Aquestive Therapeutics, Inc.
AQST
$6.51
-$0.18-2.69%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 14.71% | -26.52% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 14.71% | -26.52% | |||
| Cost of Revenue | 24.89% | -19.20% | |||
| Gross Profit | 7.38% | -31.02% | |||
| SG&A Expenses | -33.38% | 19.13% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -23.91% | 10.37% | |||
| Operating Income | 41.30% | -42.61% | |||
| Income Before Tax | 40.92% | -34.34% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 40.92% | -34.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 40.92% | -34.45% | |||
| EBIT | 41.30% | -42.61% | |||
| EBITDA | 41.60% | -43.38% | |||
| EPS Basic | 43.19% | -28.40% | |||
| Normalized Basic EPS | 43.24% | -37.96% | |||
| EPS Diluted | 43.19% | -28.40% | |||
| Normalized Diluted EPS | 43.24% | -37.96% | |||
| Average Basic Shares Outstanding | 4.01% | 4.71% | |||
| Average Diluted Shares Outstanding | 4.01% | 4.71% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||